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Resistance to antimalarial drugs is a public health problem worldwide. Molecular markers for drug-
resistant malaria, such as pfcrt and pfmdr1 polymorphisms, could serve as useful surveillance tools. To evaluate
this possibility, sequence polymorphisms in pfcrt (position 76) and pfmdr1 (positions 86, 184, 1034, 1042, and
1246) and in vitro drug sensitivities were measured for 65 Plasmodium falciparum isolates from Thailand,
Myanmar, Vietnam, and Bangladesh. The pfcrt Thr76 polymorphism was present in 97% of samples, consistent
with observations that chloroquine resistance is well established in this region. Polymorphisms in pfmdr1
clustered into four specific patterns: the wild type (category I), a Tyr86 polymorphism only (category II), a
Phe184 polymorphism only (category III), and Phe184 in combination with Cys1034 and/or Asp1042 (category
IV). Isolates in categories I and III were more sensitive to chloroquine and more resistant to mefloquine,
artesunate, and artemisinin than isolates in categories II and IV (P < 0.01). Mefloquine resistance was
significantly more common in category I and III isolates than in category II and IV isolates, with a prevalence
ratio of 14.95 (95% confidence interval, 3.88 to 57.56). These categories identified mefloquine resistance with
a sensitivity and a specificity of 94 and 91%, respectively. The pfmdr1 gene copy number was measured by
real-time PCR as a ratio of the amount of pfmdr1 DNA to the amount of lactate dehydrogenase (ldh) DNA.
Eight samples had pfmdr1 DNA/ldh DNA ratios >3. The isolates in all 8 samples fell into categories I and III
and were significantly more resistant to mefloquine, quinine, artemisinin, and artesunate and more sensitive
to chloroquine than the isolates in the 57 samples with <3 copies of the gene (P < 0.001). Thus, measurement
of pfmdr1 mutations and gene copy number may be useful for surveillance of mefloquine-resistant malaria in
Southeast Asia.
Resistance to antimalarials is spreading throughout the
world and is impeding efforts to control malaria, which causes
700,000 to 2.7 million deaths every year (3). Drug-resistant
Plasmodium falciparum is a particularly serious problem in
Southeast Asia, where strains are commonly resistant to chlo-
roquine, antifolates, quinine, and mefloquine (20).
Surveillance for drug-resistant malaria is based at present on
strict in vivo criteria for treatment failure and on measurement
of the activities of antimalarial drugs against cultured parasites
in vitro. Surveillance could be carried out more effectively by
using molecular markers, once such markers have been vali-
dated. At present, there is good evidence that mutations in two
genes (dhps and dhfr) correlate well with in vitro and in vivo
resistance to sulfadoxine-pyrimethamine and that mutations in
the gene pfcrt (especially at position 76) correlate well with in
vitro and in vivo resistance to chloroquine (for a review, see
reference 20). There is also evidence that mutations in pfmdr1
are associated with drug resistance, but the evidence is less
conclusive. Many of the studies of this relationship were per-
formed with laboratory strains of P. falciparum or with other
eukaryotic models, so the results of these experiments might
not be generalizable to naturally occurring P. falciparum iso-
lates. Also, some field studies have suggested that mutations or
amplification of this gene is associated with chloroquine resis-
tance, while others have suggested that mutations or gene
amplification is associated with increased chloroquine sensitiv-
ity (1, 6). On the other hand, there is more general agreement
that mutations in pfmdr1 are associated with altered sensitivity
to mefloquine and artemisinin derivatives in vitro, although the
role of gene amplification is not clear (1, 4, 13, 14). However,
most previous studies were small (n  20 isolates) or limited to
single geographical areas where specific polymorphisms may
have been absent. Accordingly, we chose to determine the
association of pfcrt and pfmdr1 mutations and pfmdr1 gene
amplification with in vitro sensitivity to antimalarial drugs for
a group of isolates from several areas in Southeast Asia where
malaria is endemic.
MATERIALS AND METHODS
Patient isolates. The Armed Forces Institute of Medical Sciences in Bangkok,
Thailand, has been carrying out active surveillance for resistance to antimalarials
in a variety of provinces of Thailand as well as in neighboring countries since
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1992. Over 400 patient isolates have been grown in culture, tested for their drug
sensitivities in vitro, and archived by storage in liquid nitrogen. This study
received ethical clearance from the ethical review boards of the University of
Michigan, the Walter Reed Army Institute of Research, and the Thai Ministry of
Public Health.
Field isolates were cryopreserved in a dry liquid nitrogen shipping container
and transported to the Armed Forces Institute of Medical Sciences, where they
were thawed 1 to 3 months later. In vitro drug sensitivity assays were performed
by a radioisotope microdilution technique slightly modified from that described
previously (16). Briefly, the suspension of the malaria parasite culture (0.5%
parasitemia and 1.5% hematocrit, 200 l/well) was dispensed into the wells of a
standard microtiter plate (a 96-well flat-bottom plate) predosed with duplicate
serial dilutions of the antimalarial drugs. The microtiter plate was placed in a
gas-tight box to maintain an atmosphere of 5% CO2, 5% O2, and 90% N2 and
then in an incubator (37°C). At the end of the 24th hour, the plate was tempo-
rarily removed for pulsing with [3H]hypoxanthine. The contents of each plate
were harvested after 42 to 44 h of incubation. The 50% inhibitory concentration
(IC50), IC90, etc., were estimated by nonlinear regression analysis of the incor-
porated radioactivity data. The antimalarial drugs and the ranges of concentra-
tions used were as follows: chloroquine diphosphate, 7.144 to 457.200 ng/ml;
quinine citrate, 21.438 to 1,372.000 ng/ml; mefloquine hydrochloride, 1.948 to
124.700 ng/ml; artesunate, 0.265 to 16.93 ng/ml.
For the present study, 73 stabilates were selected to maximize the statistical
power to detect differences in genotypes between sensitive and resistant isolates
by achieving an even distribution of mefloquine-resistant and -sensitive isolates.
Of these 73 stabilates, cultures were successfully obtained from 63. In addition,
two laboratory strains originally obtained from Thai isolates, isolates W2 and
PH6, were used. The isolates in these cultures were then retested for their
sensitivities to chloroquine, mefloquine, quinine, artesunate, and artemisinin in
vitro. There were good correlations between sensitivities before and after cryo-
preservation for mefloquine, quinine artesunate, and artemisinin, while the cor-
relations were less good for chloroquine. Strains with the following assay results
both in the initial test and in the repeat test were considered resistant to anti-
malarials: mefloquine, IC50  20 ng/ml or IC90  80 ng/ml; quinine, IC50  500
or IC90  1,000 ng/ml; and chloroquine, IC50  80.
Genetic polymorphisms. DNA was obtained from each culture by using
QIAamp DNA mini kits (Qiagen, Valencia, Calif.). Samples were genotyped for
msp1, msp2, and glurp by the methods described by Snounou et al. (15). PCR
amplification and direct sequencing were used to determine the sequences at a
single pfcrt polymorphic site (position 76) and five pfmdr1 polymorphic sites
(positions 86, 184, 1034, 1042, and 1246), as described previously (8). The
sequences at all loci could be determined for 61 isolates plus laboratory strains
W2 and PH6. For one isolate, the sequence at position 184 could not be ob-
tained, and for a second isolate, the sequences at positions 1034 and 1042 could
not be obtained.
Real-time PCR. Real-time PCR was performed with an ABI PRISM 7000
sequence detection system (Applied Biosystems, Foster City, Calif.). This system
uses a fluorescence-based PCR method that measures the rate of gene amplifi-
cation; as more amplicons are made, the DNA-bound reporter dye and quencher
are separated, generating fluorescence. The rate at which fluorescence increases
is related to the number of gene copies initially present (2). Primers and fluo-
rescence-labeled probes were designed by using Primer Express software (ver-
sion 2.0; Applied Biosystems, Foster City, Calif.) to amplify the P. falciparum
multidrug resistance (pfmdr1) and lactate dehydrogenase (ldh) genes (Table 1).
Probes were synthesized by Applied Biosystems and labeled in the standard
manner with a reporter dye (6-carboxyfluorescein [FAM]) at the 5 end and a
quencher dye (6-carboxytetramethylrhodamine [TAMRA]) at the 3 end. The
primers were obtained from Qiagen. The primer and probe concentrations were
optimized according to the protocol recommended for the TaqMan Universal
PCR Master Mix (Applied Biosystems).
The reagents used for each unknown sample or standard were 1 TaqMan
Universal Master Mix (2; Applied Biosystems); 300 nM forward primer; 300
nM reverse primer; 250 nM TaqMan probe; and distilled, sterile water (Sigma,
St. Louis, Mo.). The total reaction volume was 50 l. The reaction mixtures were
prepared at 4°C in a 96-well optical reaction plate (Applied Biosystems) covered
with optical adhesive covers (Applied Biosystems). The thermal cycling condi-
tions were 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and
60°C for 1 min. The threshold was set to optimize the threshold cycle (CT) value
for the first standardization reaction, and all subsequent CT values were obtained
by using the same threshold value.
In order to determine the reproducibility of the real-time PCR, 160 amplifi-
cations of each gene were performed with P. falciparum strain 3D7 DNA, which
was extracted and purified from culture in phosphate-buffered saline with Qiagen
DNA Mini kits, as stated in the spin protocol for blood and body fluids. The P.
falciparum gene copy number was calculated to be 8,000 copies/ng of DNA on
the basis of a genome size of 1.06  106 bp (www.ncbi.nlm.nih.gov). Five 10-fold
serial dilutions of P. falciparum 3D7 DNA were made, so that there were 8, 80,
800, 8,000, or 80,000 copies of genome per reaction mixture. The ldh DNA and
pfmdr1 DNA in paired standard wells were amplified 40 times (quadruplicate
reactions per plate times 10 reaction plates) for each of the four DNA concen-
trations (80 to 80,000 genome copies). Amplifications were successful for 157 of
160 reactions. The CT values for the reactions with ldh and pfmdr1 were calcu-
lated with ABI Prism 7000 SDS software, with a threshold value of 0.2000 and a
reference baseline reading of cycles 6 to 15. The change in the CT value (CT)
was calculated by subtracting the CT for a given ldh DNA concentration from the
paired CT for the same pfmdr1 DNA concentration. (Since the CT is proportional
to the log of the concentration, CT is equivalent to the log of the ratio.) A
histogram (Fig. 1A) of the CTs was made and used to calculate standard
deviations and means by using SAS software (version 8; SAS, Inc., Cary, N.C.).
The distribution shown is due to assay variability.
Since the ratio of the pfmdr1 gene copy number to the ldh gene copy number
(pfmdr1/ldh ratios) is the ultimate end point, calculations were made to deter-
mine the minimal detectable ratio. CTs were calculated for different pfrmdr1/ldh
ratios (10,000:1, 1,000:1, 100:1, 10:1, 1:1) by pairing and subtracting the CT for a
low concentration of ldh from the CT for a high concentration of pfmdr1 by using
the same data obtained as described above plus the CT data for eight copies of
ldh. For each ratio, mean CTs were plotted against the copy number ratio and
were found to fit to the equation CT  	1.6145 ln(copy number ratio)  2.8565
by using Excel Office 2000 software.
The pfmdr1 and ldh amplification reactions were run in duplicate by using 1-l
aliquots of DNA from each clinical sample. CTs were calculated as described
above, and the duplicate values were averaged. CTs which were more than 2
standard deviations beyond the mean (95% confidence interval [CI]) calculated
from the data in Fig. 1A were considered significantly different from 1.
Statistical analysis. Statistical analyses were conducted with SAS software
(version 8; SAS, Inc.). Nonnormally distributed IC50 data were assessed by
Wilcoxon rank sum tests. Group differences in the percentage of resistant iso-
lates and IC50s were assessed by the chi-square test. Prevalence ratios were
estimated for the association between genetic markers and drug susceptibility
phenotypes.
RESULTS
Polymorphisms. Of the 65 isolates successfully cultured, am-
plified, and sequenced, 39 were from Thailand, 14 were from
TABLE 1. Primers and probes used for real-time PCR
Primer or probe Sequence
Primers
LDH-F ........................................................................................ACG ATT TGG CTG GAG CAG AT
LDH-R........................................................................................TCT CTA TTC CAT TCT TTG TCA CTC TTT C
PF-R............................................................................................TCT CCT TCG GTT GGA TCA TAA AG
PF-F ............................................................................................TTA AGT TTT ACT CTA AAA GAA GGG AAA ACA TAT
Probes
PF-FAM......................................................................................FAM-CAT TTG TGG GAG AAT CAG GTT GTG GGA AAT-TAMRA
LDH-FAM .................................................................................FAM-AGT AAT AGT AAC AGC TGG ATT TAC CAA GGC CCC A-TAMRA
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Myanmar (18), 7 were from Bangladesh (11), and 5 were from
Vietnam (19). There were no associations between the msp1,
msp2, or glurp types of the strains or the degree of clonality and
drug resistance (data not shown).
Mutations in both pfcrt and pfmdr1 were quite common (Fig.
2). Ninety-seven percent (63 of 65) of the samples contained
the Thr76 polymorphism in pfcrt. pfmdr1 polymorphisms Tyr86
and Phe184 were each present in about one-third of the sam-
ples. Cys1034 and Asp1042 were present in 9 and 15% of the
samples, respectively, while no polymorphisms were found at
position 1246. None of the amplicons gave mixed sequences at
any of these loci.
Polymorphisms in pfmdr1 clustered into four specific pat-
terns without variation. We arbitrarily named these specific
patterns (Table 2). The wild-type pattern (Asn86, Tyr184,
Ser1034, Asn1042) was classified as category I. Isolates which
had the Tyr86 polymorphism (and which had no polymor-
phisms at any of the other sites) were classified as category II.
Isolates with the Phe184 polymorphism alone were classified as
category III. The only multiple polymorphism observed among
these isolates was Phe184 in combination with Cys1034 and/or
Asp1042; isolates with this pattern were classified as category
IV (Table 2). The two laboratory strains, strains W2 and PH6,
fit into categories II and IV, respectively. Both isolates with
incomplete sequences had the Tyr86 polymorphism, and no
other polymorphism was detected. Thus, they were both pre-
sumed to be in category II.
There were significant differences in the IC50s between the
different categories. The IC50s of mefloquine, artemisinin, and
FIG. 1. Frequency distribution of CTs calculated from real-time
PCR amplifications of pfmdr1 and ldh genes. (A) Histogram of 157
CTs calculated from standard DNA, showing a normal distribution;
(B) histogram of isolates. The arrows point to samples which are more
than 2 standard deviations below the mean.
FIG. 2. Prevalence of specific point mutations in pfcrt and pfmdr1. No mutations were observed at pfmdr1 position 1246 (data not shown).




86 184 1034 1042
I Asn Tyr Ser Asn 17
II Tyr Tyr Ser Asn 23
III Asn Phe Ser Asn 15
IV Asn Phe Cys Asp 10
Asn Phe Cys Asn
Asn Phe Ser Asp
a The mutated amino acids (in boldface) and the number of isolates in each
category are shown.
2420 PICKARD ET AL. ANTIMICROB. AGENTS CHEMOTHER.
artesunate were significantly higher for the isolates in catego-
ries I and III than for the isolates in categories II and IV
(one-sided P values, 0.0001, 0.0006, and 0.0001, respec-
tively) (Table 3). The opposite was true for chloroquine (P 
0.007), while the quinine IC50 data did not follow any specific
pattern. Thus, isolates in categories I and III are relatively
more resistant to mefloquine, artemisinin, and artesunate and
relatively more sensitive to chloroquine.
We reasoned that under mefloquine pressure, isolates in the
wild-type category (category I) could have developed the cat-
egory II mutation; in the same way, the isolates with the cat-
egory III mutation present under chloroquine pressure could
have developed additional polymorphisms under mefloquine
pressure, resulting in the category IV pattern. Because the
isolates in categories I and III showed similar resistance pat-
terns, while the isolates in categories II and IV also had similar
resistance patterns, we collapsed these two sets of categories to
test the hypothesis that there is an association between pfmdr1
polymorphisms and drug resistance.
The estimated risk of resistance was higher for isolates in
categories I and III than for isolates in categories II and IV
(Table 3), with prevalence ratios of 14.95 (95% CI, 3.88 to
57.56) for mefloquine and 1.44 for quinine (95% CI, 0.51 to
4.08). In contrast, the estimated risk of resistance to chloro-
quine was lower for isolates in categories I and III than for
isolates in categories II and IV (prevalence ratio, 0.94; 95% CI,
0.86 to 1.03). Thus, there was a strong association between
mutation category and the prevalence of mefloquine resistance
and a weaker association between mutation category and the
prevalence of quinine and chloroquine resistance.
Only two isolates (3%) had the wild-type pfcrt genotype
(Lys76). Both of these isolates were chloroquine sensitive, qui-
nine sensitive, and mefloquine resistant. One isolate fell into
pfmdr1 category I, and the other isolate fell into category III.
Real-time PCR to determine pfmdr1/ldh ratio. A total of 157
CTs were determined from the concentration-response exper-
iments run with standard DNA (Fig. 1A), yielding a mean CT
of 2.82 with a 95% CI of 1.05 to 4.57. CT values that fall below
the lower CI are indicative of high pfmdr1/ldh ratios. pfmdr1/
ldh ratios yielding CT values that fall within the CI are not
considered statistically significantly different from 1. Only
pfmdr1/ldh ratios of 3.06 or more would yield clinical CT
values less than 1.05. Thus, the sensitivity limit of this assay is
a pfmdr1/ldh ratio of 3.
The pfmdr1 and ldh genes were successfully amplified from
all DNA samples. The frequency distributions for CT values
are shown in Fig. 1B. The isolates in 8 of 65 samples (12.3%)
had CT values which were below the 95% confidence limit
(i.e., less than 1.05), which is indicative of pfmdr1/ldh ratios
between 3 and 4.2. Five of these isolates were in category I, and
three were in category III. The IC50s were compared for three
groups: categories I and III with amplification, categories I and
III without amplification, and categories II and IV without
amplification. The IC50s of all drugs examined were signifi-
cantly different across these three categories (Table 4). The
mefloquine, quinine, artemisinin, and artesunate IC50s were
TABLE 3. Median IC50s and percent resistance for isolates in four catagories
Category











I (n  17) 100 60.68 (49.64–69.90) 35 188.62 (104.44–271.88) 76 56.40 (47.08–73.92) 1.74 (1.10–2.04) 4.51 (2.47–4.84)
II (n  23) 0 15.79 (11.43–19.56) 4 94.68 (77.79–107.83) 91 88.19 (73.09–107.83) 0.73 (0.54–1.40) 1.43 (1.06–2.69)
III (n  15) 80 59.51 (30.87–73.96) 31 148.87 (70.07–239.88) 81 70.92 (19.38–92.08) 2.57 (1.80–3.85) 2.57 (1.80–3.85)
IV (n  10) 20 19.44 (10.01–24.70) 11 184.36 (141.28–233.41) 89 70.10 (63.69–98.97) 0.97 (0.80–1.30) 0.85 (0.64–0.93)
P value for
differencec
0.001 0.001 0.266 0.002 0.001 0.007 0.001 0.011
a % R, percentage of resistant isolates.
b For artemisinin and artesunate, there are no established in vitro cut offs for resistance and sensitivity.
c P-values were determined by chi-square analysis for percentage of resistant isolates and analysis of variance for IC50s.
TABLE 4. Median IC50s and percent resistance for isolates categorized by pfmdr1 gene amplification
Category





% R Median IC50(interquartile range) % R
Median IC50
(interquartile range) Artemisinin Artesunate
II and IV, no amplification
(n  33)
6.1 16.86 (11.13–20.45) 15.2 112.01 (80.98–143.74) 100 84.37 (68.22–107.12) 0.82 (0.64–1.09) 1.32 (0.83–2.13)
I and III, no amplification
(n  24)
87.5 53.01 (34.15–62.79) 16.7 144.35 (71.96–199.15) 91.7 69.06 (50.87–86.92) 1.18 (0.74–1.92) 2.48 (1.71–4.60)
I and III, amplification
(n  8)
100 72.13 (64.77–99.21) 37.5 289.31 (253.44–360.07) 100 57.55 (43.51–64.92) 1.89 (1.28–2.76) 5.63 (3.33–8.33)
P value for differenceb 0.0001 0.0001 0.3280 0.0010 0.3654 0.0029 0.0008 0.0001
a % R, percentage of resistant isolates.
b P values were determined by Fisher’s exact chi-square test for percentage of resistant isolates and the Wilcoxon rank sum test for IC50s.
VOL. 47, 2003 ANTIMALARIAL RESISTANCE AND pfmdr1 2421
the highest for isolates in categories I and III with amplifica-
tion, moderate for isolates in categories I and III without
amplification, and lowest for isolates in categories II and IV
without amplification (P values, 0.0001, 0.001, 0.0008, and
0.0001, respectively) (Table 4). Chloroquine exhibited the
opposite pattern, with the lowest chloroquine IC50s being for
isolates in categories I and III with amplification and the high-
est chloroquine IC50s being for isolates in categories II and IV
without amplification.
Evaluation for the presence of category I and III genotypes
may be useful tool in surveillance for mefloquine resistance.
The presence of these genotypes has a positive predictive value
of 91% for this group of isolates, with a sensitivity of 94% and
a specificity of 91% for the detection of in vitro mefloquine
resistance. For quinine resistance and chloroquine sensitivity,
on the other hand, the values are much lower. Because all
isolates whose DNA was amplified were mefloquine resistant,
the pfmdr1 gene copy number has a positive predictive value
and a specificity of 100% for the detection of mefloquine
resistance; however, it is less useful than the genotype for
surveillance because of a sensitivity of only 26%.
DISCUSSION
Among 65 cultured isolates from Southeast Asia, almost all
contained the pfcrt polymorphism at position 76. Polymor-
phisms were found at four loci in the pfmdr1 gene and occurred
in four specific patterns (Table 2). The isolates with two pat-
terns (categories I and III) tended to be more resistant to
mefloquine, artesunate, and artemisinin, while the isolates with
two others (categories II and IV) tended to be more resistant
to chloroquine. Our data also demonstrate that isolates with
increased pfmdr1 copy numbers tend to be more resistant to
mefloquine, quinine, artesunate, and artemisinin and more
sensitive to chloroquine than isolates without increased pfmdr1
copy numbers.
An association between the polymorphism that comprised
category II (Tyr86) and mefloquine susceptibility had previ-
ously been suggested, but the strength of this association was
never precisely quantified (for a review, see reference 20).
Attempts to answer the question related to pfmdr1 gene am-
plification also have a history of conflicting results. Some stud-
ies have reported increased copy numbers with selection for
mefloquine resistance (5, 12), while others have not (9, 10).
In this study, isolates that were in categories I or III were
15-fold more likely to be mefloquine resistant in vitro. This is
the strongest association ever reported between pfmdr1 and
resistance to antimalarials. The presence of these genotypes
correctly identifies 94% of the mefloquine-resistant isolates in
vitro, while the absence of these genotypes correctly identifies
91% of the mefloquine-sensitive isolates in vitro.
We also found a robust association between pfmdr1 copy
number and drug resistance. Increased pfmdr1 copy numbers
were found only among isolates in the two categories (catego-
ries I and III) in which isolates already displayed increased
mefloquine resistance. Within categories I and III, isolates
with pfmdr1 amplification were significantly more resistant to
mefloquine, quinine, artemisinin, and artesunate than isolates
without pfmdr1 amplification. This suggests that pfmdr1 ampli-
fication may occur secondarily as a way to achieve greater
levels of resistance. However, pfmdr1 amplification appears to
be less useful as a surveillance tool, with a sensitivity of only
26%. One possible reason for this is the fact that our real-time
PCR assay could only reliably detect pfmdr1/ldh ratios 3.
Improvements to the assay might improve its sensitivity.
The distribution of pfmdr1 polymorphisms found here can
be compared constructively with those found in a previous
study, in which the pfmdr1 genotypes of 54 isolates from the
northwestern border of Thailand and Myanmar were reported
(13). Of the 54 sequences published, 52 fit into the categories
described in this paper: 28 (54%) were category I, 5 (10%)
were category II, and 19 (37%) were category III or IV. That
study did find increased pfmdr1 copy numbers in mefloquine-
resistant parasites; similar to the present study, isolates with
increased copy numbers were all wild type at position 86 (cor-
responding to possible category I or III isolates) (13).
The lack of a polymorphism at position 1246 in this study
supported previous reports from Asia, suggesting that this
polymorphism may not be important for isolates from this
region (4, 13, 17). Also, the coexistence of elevations in me-
floquine, artemisinin, and artesunate IC50s for the same cate-
gories of isolates is also consistent with previous observations
(1, 7, 16, 21).
Since the isolates in category IV contain the one mutation
found among the isolates in category III plus other mutations,
category IV isolates could have derived from category III iso-
lates. Different geographic distributions were found for the
different classes and may support this idea. The most striking
geographic differences were between Yala (in southern Thai-
land) and Borai (on the Thai-Cambodian border): eight of
eight isolates in samples selected from among those that orig-
inated in Yala were category II, while five of five isolates in
samples from Borai were category III or IV. Circumstantial
support for the evolution of genotype is offered by the only two
chloroquine-sensitive isolates, which were mefloquine resistant
and which were in categories I and III.
The interpretation of our results must bear certain consid-
erations. First, isolates were chosen to provide the broadest
range of in vitro sensitivities to mefloquine. Thus, the power
for discriminating between mefloquine-sensitive and -resistant
isolates was high. This study was designed to test the hypoth-
esis that there is an association between mefloquine resistance
and the pfmdr1 genotype. Because of this, the prevalence of
sensitive and resistant isolates in this study does not represent
the prevalence in the Southeast Asian populations from which
they were drawn. Our observation that polymorphisms were
more significantly associated with resistance to mefloquine
than with resistance to other drugs may simply be due to our
selection criterion. Second, the observation that polymor-
phisms fell into only four patterns may not be generalizable;
studies with larger numbers of samples from Southeast Asia or
samples from other regions might reveal other patterns. Third,
like other studies in Southeast Asia, this study was not able to
assess the relative importance of pfcrt mutations, given the high
percentage of isolates with the Thr76 polymorphism. Fourth, it
is possible that pfmdr1 mutations may not be responsible for
mefloquine resistance but may only be in linkage disequilib-
rium with other determinants that do cause resistance. Finally,
the in vitro resistance studied here may not correlate with in
vivo resistance. Future studies are needed to determine the
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association between pfmdr1 polymorphisms and in vivo resis-
tance.
In summary, our data suggest that categories of polymor-
phisms in pfmdr1 exist in Southeast Asia and that isolates
resistant to mefloquine and chloroquine have opposite genetic
patterns. Chloroquine use may have selected for pfmdr1 poly-
morphism categories II and IV, but when mefloquine became
widely used, the selection pressure was put on isolates in cat-
egories I and III. The strong association observed suggests that
categories I and III, along with pfmdr1 gene amplification,
could be key determinants of resistance to mefloquine in
Southeast Asia. Future studies should more rigorously study
this association. Furthermore, the patterns of the polymor-
phisms reported here have high degrees of sensitivity and spec-
ificity for the detection of mefloquine resistance and might
serve as useful epidemiological tools.
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